Join to View Full Profile
9200 W Wisconsin AveNeoplasic DiseasesMilwaukee, WI 53226
Phone+1 414-805-4600
Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nirav Shah is an Oncologist specializing in Hematologic Oncology, based in Milwaukee, WI. He educated at the University of Illinois College of Medicine, class of 2008, and gained further experience during his residency at Massachusetts General Hospital and fellowship at the University of Pennsylvania Health System. He worked as an instructor at Northwestern Memorial Hospital. His areas of expertise include non-Hodgkin and Hodgkin lymphoma, immunotherapy, hematologic oncology, stem cell transplant, and cellular therapy. He has multiple publications in the field of oncology and has been involved in several clinical trials focused on B-cell malignancies and CAR-T cell therapies.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2012 - 2015
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
University of Illinois College of MedicineClass of 2008
Certifications & Licensure
WI State Medical License 2015 - 2025
PA State Medical License 2012 - 2016
IL State Medical License 2011 - 2014
MA State Medical License 2010 - 2011
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Start of enrollment: 2017 Oct 16
- Long-term Follow-up Study of Patients Receiving CAR-T Cells Start of enrollment: 2017 Dec 01
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22
- Join now to see all
Publications & Presentations
PubMed
- Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis.Kalyan V Nadiminti, Kwang W Ahn, Jinalben Patel, Qinghua Lian, Evandro Bezerra
Transplantation and Cellular Therapy. 2025-08-05 - 2 citationsItacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.Matthew J Frigault, Richard T Maziarz, Jae H Park, Aleksandr Lazaryan, Nirav N Shah
Blood. 2025-07-24 - 1 citationsPhase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.Nirav N Shah, Alfredo S Colina, Bryon D Johnson, Aniko Szabo, Fateeha Furqan
Journal of Clinical Oncology. 2025-07-10
Lectures
- Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
- Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Authored Content
- The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell MalignanciesJuly 2025
Press Mentions
Dual-Targeted, Onsite-Manufactured CAR-T Shows ‘Potential’ in Mantle Cell LymphomaMay 12th, 2025- Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 CAR T Cells in Relapsed/Refractory Mantle Cell LymphomaApril 21st, 2025
- Ask an Expert: Cellular Therapy LabJanuary 7th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
